Anaptysbio (ANAB) Cash from Investing Activities (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Cash from Investing Activities data on file, last reported at $35.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 135.62% year-over-year to $35.0 million; the trailing twelve-month figure through Mar 2026 stood at $248.2 million (up 496.14% YoY), and the FY2025 full-year result was $228.0 million, up 139.03% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $35.0 million, down from $73.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $103.3 million in Q3 2025 and bottomed at -$312.9 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $30.6 million (2023), against an average of $6.4 million.
• The widest annual swing landed in 2022, when Cash from Investing Activities slumped 651.59%; it then surged 1590.7% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $21.5 million in 2022, then soared by 128.77% to $49.2 million in 2023, then slumped by 159.77% to -$29.4 million in 2024, then surged by 350.03% to $73.5 million in 2025, then sank by 52.4% to $35.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $35.0 million (Q1 2026), $73.5 million (Q4 2025), and $103.3 million (Q3 2025), per Business Quant data.

Peer Comparison